In this week's episode we’ll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results from the induction phase of the risk-adapted MIDAS trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma; and a link between splicing factor mutations and competitive fitness in myelodysplastic syndrome stem cells.
Featured articles:
View all episodes
By American Society of Hematology
4.1
4848 ratings
In this week's episode we’ll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results from the induction phase of the risk-adapted MIDAS trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma; and a link between splicing factor mutations and competitive fitness in myelodysplastic syndrome stem cells.
Featured articles:
133 Listeners
315 Listeners
26 Listeners
488 Listeners
91 Listeners
1,110 Listeners
3 Listeners
191 Listeners
349 Listeners
1 Listeners
1 Listeners
28 Listeners
169 Listeners
49 Listeners
3 Listeners